Optimizing local control of high-risk prostate cancers through multimodal treatments.

[Optimizing local control of high-risk prostate cancers through multimodal treatments]. Prog Urol. 2019 Jun;29 Suppl 1:S8-S19 Authors: Latorzeff I Abstract Prostate cancer is a sensitive adenocarcinoma, in more than 80 % of cases, to chemical castration, due to its hormone dependence. Locally advanced and/or high-risk cancer is defined based on clinical stage, initial PSA value or high Gleason score. Hormone therapy associated with radiation therapy is the standard of management and improves local control, reduces the risk of distant metastasis and improves specific and overall survival. Duration of hormone therapy, dose level of radiation therapy alone or associated with brachytherapy are controversial data in the literature. Radical prostatectomy surgery is a therapeutic option that must be performed with extensive lymph node dissection and is often part of a multimodal care sequence. The therapeutic choice, multidisciplinary, depends on the age and co-morbidity of the patient, the prognostic criteria of the pathology and the urinary function of the patient. Current research focuses on optimizing local and distant control of these aggressive forms and incorporates neo-adjuvant or adjuvant chemotherapy and also new hormone therapies. PMID: 31307631 [PubMed - in process]
Source: Progres en Urologie - Category: Urology & Nephrology Tags: Prog Urol Source Type: research

Related Links:

Morphological and functional alterations of the prostate tissue during clinical progression in hormonally-naïve, hormonally-treated and castration-resistant patients with metastatic prostate cancer. Oncol Lett. 2020 Nov;20(5):201 Authors: KorĨek M, Sekerešová M, Makarevich AV, Gavurová H, Olexíková L, Pivko J, Barreto L Abstract Since commony used tools in oncological practice for the diagnosis of castration-resistent prostatic acinar adenocarcinoma are based on clinical criteria, such as castrate testosterone level, continuous rise in serum prostate-specific an...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Verma A, Najahi-Missaoui W, Cummings BS, Somanath PR Abstract Metastatic prostate cancer (PCa) has a very high mortality rate in men, in Western countries and lacks reliable treatment. The advanced-stage PCa cells overexpress P21 (RAC1) activated kinase-1 (PAK1) and secreted phospholipase A2 (sPLA2) suggesting the potential utility of pharmacologically targeting these molecules to treat metastatic PCa. The small molecule, inhibitor targeting PAK1 activation-3 (IPA3) is a highly specific allosteric inhibitor of PAK1; however, it is metabolically unstable once in the plasma thus, limiting its utility as a ch...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Abstract F-box and WD repeat domain containing (FBXW) family of E3 ligases has 10 members that ubiquitinate substrate proteins for proteasome-mediated degradation. Publicly archived datasets from The Cancer Genome Atlas (TCGA), Prostate Cancer Transcriptome Atlas (PCTA), and cBioPortal were analyzed for mRNA expression and genetic alterations of 10 FBXW genes. We found that FBXW7 mRNA expression was significantly decreased in primary prostate cancers compared to normal prostate tissues, whereas mRNA expression of FBXW8-10 was significantly increased in primary prostate cancers compared to normal prostate tissues. ...
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: Am J Clin Exp Urol Source Type: research
In this study of Chinese men with biochemical recurrence, added value for the detection of lesions compatible with sites of PCa was found with68Ga-PSMA-11 PET/CT over conventional imaging. The observed patterns of disease spread may have implications for understanding the biology of early prostate cancer metastasis.
Source: Medical Oncology - Category: Cancer & Oncology Source Type: research
Condition:   Prostate Adenocarcinoma Intervention:   Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT) Sponsor:   Alpha Tau Medical LTD. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Galectin-3 (Gal-3) is an extracellular matrix glycan-binding protein with several immunosuppressive and pro-tumor functions. The role of Galectin-3 in cancer stem-like cells (CSCs) is poorly investigated. Here, we show that prostate CSCs also colonizing prostate-draining lymph nodes of transgenic adenocarcinoma of the mouse prostate (TRAMP) mice overexpress Gal-3. Gal-3 contributes to prostate CSC-mediated immune suppression because either Gal-3 silencing in CSCs, or co-culture of CSCs and T cells in the presence of the Gal-3 inhibitor N-Acetyl-D-lactosamine rescued T cell proliferation. N-Acetyl-D-lactosamine also rescued...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
CONCLUSION: Systematic biopsies should still be considered in patients with PI-RADS 1/2 findings. Our findings also suggest a stronger benefit of the combined strategy of targeted and systematic biopsies than the findings of previous studies concerning the detection of CSPCa in biopsy-naïve patients. PMID: 32865086 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Urology - Category: Urology & Nephrology Tags: Scand J Urol Source Type: research
A 72-year-old man with a history of coronary artery disease requiring angioplasty and 2 stents in 2017 (no history of myocardial infarction and no ongoing cardiac issues) received a diagnosis of National Comprehensive Cancer Network unfavorable intermediate-risk (UIR) prostate adenocarcinoma (Gleason score 4 + 3 in 4 of 12 cores, cT2a, prostate-specific antigen 8.2 mg/L) in October 2019. He refused surgery and met with a radiation oncologist. After prolonged discussions about his prostate cancer risk and his cardiac history, he elected for stereotactic body radiation therapy (SBRT) without androgen deprivation therapy1 and...
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Gray Zone Source Type: research
Conclusion: Ultrahypofractionated radiotherapy, delivered with flattening filter free-volumetric modulated arc therapy and gated by electromagnetic transponders, is a valid option for intermediate-risk prostate cancer.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Genitourinary Source Type: research
This study revealed a mechanism by which t-NEPC can develop through the LIN28B/let-7/SOX2 axis that regulates a cancer cell stem-like gene network, highlighting LIN28B as a potential therapeutic target in t-NEPC.
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
More News: Adenocarcinoma | Brachytherapy | Cancer | Cancer & Oncology | Chemistry | Chemotherapy | Hormonal Therapy | Hormones | Pathology | Prostate Cancer | Prostatectomy | Radiation Therapy | Urology & Nephrology